1 Market Overview of Targeted Drugs for Multiple Myeloma 1.1 Targeted Drugs for Multiple Myeloma Market Overview 1.1.1 Targeted Drugs for Multiple Myeloma Product Scope 1.1.2 Targeted Drugs for Multiple Myeloma Market Status and Outlook 1.2 Global Targeted Drugs for Multiple Myeloma Market Size Overview by Region 2016 VS 2021VS 2027 1.3 Global Targeted Drugs for Multiple Myeloma Market Size by Region (2016-2027) 1.4 Global Targeted Drugs for Multiple Myeloma Historic Market Size by Region (2016-2021) 1.5 Global Targeted Drugs for Multiple Myeloma Market Size Forecast by Region (2022-2027) 1.6 Key Regions, Targeted Drugs for Multiple Myeloma Market Size (2016-2027) 1.6.1 North America Targeted Drugs for Multiple Myeloma Market Size (2016-2027) 1.6.2 Europe Targeted Drugs for Multiple Myeloma Market Size (2016-2027) 1.6.3 Asia-Pacific Targeted Drugs for Multiple Myeloma Market Size (2016-2027) 1.6.4 Latin America Targeted Drugs for Multiple Myeloma Market Size (2016-2027) 1.6.5 Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size (2016-2027) 2 Targeted Drugs for Multiple Myeloma Market Overview by Type 2.1 Global Targeted Drugs for Multiple Myeloma Market Size by Type: 2016 VS 2021 VS 2027 2.2 Global Targeted Drugs for Multiple Myeloma Historic Market Size by Type (2016-2021) 2.3 Global Targeted Drugs for Multiple Myeloma Forecasted Market Size by Type (2022-2027) 2.4 Immunomodulator 2.5 Proteasome Inhibitors 2.6 Histone Deacetylase Inhibitors (HDACI) 2.7 Monoclonal Antibody 2.8 Other 3 Targeted Drugs for Multiple Myeloma Market Overview by Application 3.1 Global Targeted Drugs for Multiple Myeloma Market Size by Application: 2016 VS 2021 VS 2027 3.2 Global Targeted Drugs for Multiple Myeloma Historic Market Size by Application (2016-2021) 3.3 Global Targeted Drugs for Multiple Myeloma Forecasted Market Size by Application (2022-2027) 3.4 Hospital 3.5 Drug Center 3.6 Clinic 3.7 Other 4 Targeted Drugs for Multiple Myeloma Competition Analysis by Players 4.1 Global Targeted Drugs for Multiple Myeloma Market Size by Players (2016-2021) 4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Targeted Drugs for Multiple Myeloma as of 2020) 4.3 Date of Key Players Enter into Targeted Drugs for Multiple Myeloma Market 4.4 Global Top Players Targeted Drugs for Multiple Myeloma Headquarters and Area Served 4.5 Key Players Targeted Drugs for Multiple Myeloma Product Solution and Service 4.6 Competitive Status 4.6.1 Targeted Drugs for Multiple Myeloma Market Concentration Rate 4.6.2 Mergers & Acquisitions, Expansion Plans 5 Company (Top Players) Profiles and Key Data 5.1 Celgene 5.1.1 Celgene Profile 5.1.2 Celgene Main Business 5.1.3 Celgene Targeted Drugs for Multiple Myeloma Products, Services and Solutions 5.1.4 Celgene Targeted Drugs for Multiple Myeloma Revenue (US$ Million) & (2016-2021) 5.1.5 Celgene Recent Developments 5.2 Exova 5.2.1 Exova Profile 5.2.2 Exova Main Business 5.2.3 Exova Targeted Drugs for Multiple Myeloma Products, Services and Solutions 5.2.4 Exova Targeted Drugs for Multiple Myeloma Revenue (US$ Million) & (2016-2021) 5.2.5 Exova Recent Developments 5.3 Natco Pharma 5.5.1 Natco Pharma Profile 5.3.2 Natco Pharma Main Business 5.3.3 Natco Pharma Targeted Drugs for Multiple Myeloma Products, Services and Solutions 5.3.4 Natco Pharma Targeted Drugs for Multiple Myeloma Revenue (US$ Million) & (2016-2021) 5.3.5 Intas Pharmaceuticals Recent Developments 5.4 Intas Pharmaceuticals 5.4.1 Intas Pharmaceuticals Profile 5.4.2 Intas Pharmaceuticals Main Business 5.4.3 Intas Pharmaceuticals Targeted Drugs for Multiple Myeloma Products, Services and Solutions 5.4.4 Intas Pharmaceuticals Targeted Drugs for Multiple Myeloma Revenue (US$ Million) & (2016-2021) 5.4.5 Intas Pharmaceuticals Recent Developments 5.5 Indiabulls Pharmaceutical 5.5.1 Indiabulls Pharmaceutical Profile 5.5.2 Indiabulls Pharmaceutical Main Business 5.5.3 Indiabulls Pharmaceutical Targeted Drugs for Multiple Myeloma Products, Services and Solutions 5.5.4 Indiabulls Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue (US$ Million) & (2016-2021) 5.5.5 Indiabulls Pharmaceutical Recent Developments 5.6 Cipla 5.6.1 Cipla Profile 5.6.2 Cipla Main Business 5.6.3 Cipla Targeted Drugs for Multiple Myeloma Products, Services and Solutions 5.6.4 Cipla Targeted Drugs for Multiple Myeloma Revenue (US$ Million) & (2016-2021) 5.6.5 Cipla Recent Developments 5.7 Glenmark Pharmaceuticals 5.7.1 Glenmark Pharmaceuticals Profile 5.7.2 Glenmark Pharmaceuticals Main Business 5.7.3 Glenmark Pharmaceuticals Targeted Drugs for Multiple Myeloma Products, Services and Solutions 5.7.4 Glenmark Pharmaceuticals Targeted Drugs for Multiple Myeloma Revenue (US$ Million) & (2016-2021) 5.7.5 Glenmark Pharmaceuticals Recent Developments 5.8 Dr Reddy's Laboratories 5.8.1 Dr Reddy's Laboratories Profile 5.8.2 Dr Reddy's Laboratories Main Business 5.8.3 Dr Reddy's Laboratories Targeted Drugs for Multiple Myeloma Products, Services and Solutions 5.8.4 Dr Reddy's Laboratories Targeted Drugs for Multiple Myeloma Revenue (US$ Million) & (2016-2021) 5.8.5 Dr Reddy's Laboratories Recent Developments 5.9 Qilu Pharmaceutical 5.9.1 Qilu Pharmaceutical Profile 5.9.2 Qilu Pharmaceutical Main Business 5.9.3 Qilu Pharmaceutical Targeted Drugs for Multiple Myeloma Products, Services and Solutions 5.9.4 Qilu Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue (US$ Million) & (2016-2021) 5.9.5 Qilu Pharmaceutical Recent Developments 5.10 Chia Tai-Tianqing 5.10.1 Chia Tai-Tianqing Profile 5.10.2 Chia Tai-Tianqing Main Business 5.10.3 Chia Tai-Tianqing Targeted Drugs for Multiple Myeloma Products, Services and Solutions 5.10.4 Chia Tai-Tianqing Targeted Drugs for Multiple Myeloma Revenue (US$ Million) & (2016-2021) 5.10.5 Chia Tai-Tianqing Recent Developments 5.11 Hanson Pharm 5.11.1 Hanson Pharm Profile 5.11.2 Hanson Pharm Main Business 5.11.3 Hanson Pharm Targeted Drugs for Multiple Myeloma Products, Services and Solutions 5.11.4 Hanson Pharm Targeted Drugs for Multiple Myeloma Revenue (US$ Million) & (2016-2021) 5.11.5 Hanson Pharm Recent Developments 5.12 Meidakang Huakang Pharmaceutical 5.12.1 Meidakang Huakang Pharmaceutical Profile 5.12.2 Meidakang Huakang Pharmaceutical Main Business 5.12.3 Meidakang Huakang Pharmaceutical Targeted Drugs for Multiple Myeloma Products, Services and Solutions 5.12.4 Meidakang Huakang Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue (US$ Million) & (2016-2021) 5.12.5 Meidakang Huakang Pharmaceutical Recent Developments 5.13 Shandong Kongfu Pharmaceutical 5.13.1 Shandong Kongfu Pharmaceutical Profile 5.13.2 Shandong Kongfu Pharmaceutical Main Business 5.13.3 Shandong Kongfu Pharmaceutical Targeted Drugs for Multiple Myeloma Products, Services and Solutions 5.13.4 Shandong Kongfu Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue (US$ Million) & (2016-2021) 5.13.5 Shandong Kongfu Pharmaceutical Recent Developments 5.14 J&J 5.14.1 J&J Profile 5.14.2 J&J Main Business 5.14.3 J&J Targeted Drugs for Multiple Myeloma Products, Services and Solutions 5.14.4 J&J Targeted Drugs for Multiple Myeloma Revenue (US$ Million) & (2016-2021) 5.14.5 J&J Recent Developments 5.15 Takeda 5.15.1 Takeda Profile 5.15.2 Takeda Main Business 5.15.3 Takeda Targeted Drugs for Multiple Myeloma Products, Services and Solutions 5.15.4 Takeda Targeted Drugs for Multiple Myeloma Revenue (US$ Million) & (2016-2021) 5.15.5 Takeda Recent Developments 5.16 Amgen 5.16.1 Amgen Profile 5.16.2 Amgen Main Business 5.16.3 Amgen Targeted Drugs for Multiple Myeloma Products, Services and Solutions 5.16.4 Amgen Targeted Drugs for Multiple Myeloma Revenue (US$ Million) & (2016-2021) 5.16.5 Amgen Recent Developments 5.17 Bristol Myers Squibb 5.17.1 Bristol Myers Squibb Profile 5.17.2 Bristol Myers Squibb Main Business 5.17.3 Bristol Myers Squibb Targeted Drugs for Multiple Myeloma Products, Services and Solutions 5.17.4 Bristol Myers Squibb Targeted Drugs for Multiple Myeloma Revenue (US$ Million) & (2016-2021) 5.17.5 Bristol Myers Squibb Recent Developments 5.18 Abbvie 5.18.1 Abbvie Profile 5.18.2 Abbvie Main Business 5.18.3 Abbvie Targeted Drugs for Multiple Myeloma Products, Services and Solutions 5.18.4 Abbvie Targeted Drugs for Multiple Myeloma Revenue (US$ Million) & (2016-2021) 5.18.5 Abbvie Recent Developments 5.19 Seattle Genetics 5.19.1 Seattle Genetics Profile 5.19.2 Seattle Genetics Main Business 5.19.3 Seattle Genetics Targeted Drugs for Multiple Myeloma Products, Services and Solutions 5.19.4 Seattle Genetics Targeted Drugs for Multiple Myeloma Revenue (US$ Million) & (2016-2021) 5.19.5 Seattle Genetics Recent Developments 5.20 Karyopharm Therapeutics 5.20.1 Karyopharm Therapeutics Profile 5.20.2 Karyopharm Therapeutics Main Business 5.20.3 Karyopharm Therapeutics Targeted Drugs for Multiple Myeloma Products, Services and Solutions 5.20.4 Karyopharm Therapeutics Targeted Drugs for Multiple Myeloma Revenue (US$ Million) & (2016-2021) 5.20.5 Karyopharm Therapeutics Recent Developments 5.21 PDL BioPharma 5.21.1 PDL BioPharma Profile 5.21.2 PDL BioPharma Main Business 5.21.3 PDL BioPharma Targeted Drugs for Multiple Myeloma Products, Services and Solutions 5.21.4 PDL BioPharma Targeted Drugs for Multiple Myeloma Revenue (US$ Million) & (2016-2021) 5.21.5 PDL BioPharma Recent Developments 5.22 Roche 5.22.1 Roche Profile 5.22.2 Roche Main Business 5.22.3 Roche Targeted Drugs for Multiple Myeloma Products, Services and Solutions 5.22.4 Roche Targeted Drugs for Multiple Myeloma Revenue (US$ Million) & (2016-2021) 5.22.5 Roche Recent Developments 5.23 Sumitomo 5.23.1 Sumitomo Profile 5.23.2 Sumitomo Main Business 5.23.3 Sumitomo Targeted Drugs for Multiple Myeloma Products, Services and Solutions 5.23.4 Sumitomo Targeted Drugs for Multiple Myeloma Revenue (US$ Million) & (2016-2021) 5.23.5 Sumitomo Recent Developments 5.24 Merck 5.24.1 Merck Profile 5.24.2 Merck Main Business 5.24.3 Merck Targeted Drugs for Multiple Myeloma Products, Services and Solutions 5.24.4 Merck Targeted Drugs for Multiple Myeloma Revenue (US$ Million) & (2016-2021) 5.24.5 Merck Recent Developments 5.25 Biogen 5.25.1 Biogen Profile 5.25.2 Biogen Main Business 5.25.3 Biogen Targeted Drugs for Multiple Myeloma Products, Services and Solutions 5.25.4 Biogen Targeted Drugs for Multiple Myeloma Revenue (US$ Million) & (2016-2021) 5.25.5 Biogen Recent Developments 5.26 Schering-Plough 5.26.1 Schering-Plough Profile 5.26.2 Schering-Plough Main Business 5.26.3 Schering-Plough Targeted Drugs for Multiple Myeloma Products, Services and Solutions 5.26.4 Schering-Plough Targeted Drugs for Multiple Myeloma Revenue (US$ Million) & (2016-2021) 5.26.5 Schering-Plough Recent Developments 5.27 Glaxo 5.27.1 Glaxo Profile 5.27.2 Glaxo Main Business 5.27.3 Glaxo Targeted Drugs for Multiple Myeloma Products, Services and Solutions 5.27.4 Glaxo Targeted Drugs for Multiple Myeloma Revenue (US$ Million) & (2016-2021) 5.27.5 Glaxo Recent Developments 5.28 Chiron 5.28.1 Chiron Profile 5.28.2 Chiron Main Business 5.28.3 Chiron Targeted Drugs for Multiple Myeloma Products, Services and Solutions 5.28.4 Chiron Targeted Drugs for Multiple Myeloma Revenue (US$ Million) & (2016-2021) 5.28.5 Chiron Recent Developments 6 North America 6.1 North America Targeted Drugs for Multiple Myeloma Market Size by Country (2016-2027) 6.2 United States 6.3 Canada 7 Europe 7.1 Europe Targeted Drugs for Multiple Myeloma Market Size by Country (2016-2027) 7.2 Germany 7.3 France 7.4 U.K. 7.5 Italy 7.6 Russia 7.7 Nordic 7.8 Rest of Europe 8 Asia-Pacific 8.1 Asia-Pacific Targeted Drugs for Multiple Myeloma Market Size by Region (2016-2027) 8.2 China 8.3 Japan 8.4 South Korea 8.5 Southeast Asia 8.6 India 8.7 Australia 8.8 Rest of Asia-Pacific 9 Latin America 9.1 Latin America Targeted Drugs for Multiple Myeloma Market Size by Country (2016-2027) 9.2 Mexico 9.3 Brazil 9.4 Rest of Latin America 10 Middle East & Africa 10.1 Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size by Country (2016-2027) 10.2 Turkey 10.3 Saudi Arabia 10.4 UAE 10.5 Rest of Middle East & Africa 11 Targeted Drugs for Multiple Myeloma Market Dynamics 11.1 Targeted Drugs for Multiple Myeloma Industry Trends 11.2 Targeted Drugs for Multiple Myeloma Market Drivers 11.3 Targeted Drugs for Multiple Myeloma Market Challenges 11.4 Targeted Drugs for Multiple Myeloma Market Restraints 12 Research Finding /Conclusion 13 Methodology and Data Source 13.1 Methodology/Research Approach 13.1.1 Research Programs/Design 13.1.2 Market Size Estimation 13.1.3 Market Breakdown and Data Triangulation 13.2 Data Source 13.2.1 Secondary Sources 13.2.2 Primary Sources 13.3 Disclaimer 13.4 Author List

List of Tables Table 1. Global Market Targeted Drugs for Multiple Myeloma Market Size (US$ Million) Comparison by Region 2016 VS 2021 VS 2027 Table 2. Global Targeted Drugs for Multiple Myeloma Market Size by Region (2016-2021) & (US$ Million) Table 3. Global Targeted Drugs for Multiple Myeloma Market Size Share by Region (2016-2021) Table 4. Global Targeted Drugs for Multiple Myeloma Forecasted Market Size by Region (2022-2027) & (US$ Million) Table 5. Global Targeted Drugs for Multiple Myeloma Forecasted Market Size Share by Region (2022-2027) Table 6. Global Targeted Drugs for Multiple Myeloma Market Size (US$ Million) by Type: 2016 VS 2021 VS 2027 Table 7. Global Targeted Drugs for Multiple Myeloma Market Size by Type (2016-2021) & (US$ Million) Table 8. Global Targeted Drugs for Multiple Myeloma Revenue Market Share by Type (2016-2021) Table 9. Global Targeted Drugs for Multiple Myeloma Forecasted Market Size by Type (2022-2027) & (US$ Million) Table 10. Global Targeted Drugs for Multiple Myeloma Revenue Market Share by Type (2022-2027) Table 11. Global Targeted Drugs for Multiple Myeloma Market Size (US$ Million) by Application: 2016 VS 2021 VS 2027 Table 12. Global Targeted Drugs for Multiple Myeloma Market Size by Application (2016-2021) & (US$ Million) Table 13. Global Targeted Drugs for Multiple Myeloma Revenue Market Share by Application (2016-2021) Table 14. Global Targeted Drugs for Multiple Myeloma Forecasted Market Size by Application (2022-2027) & (US$ Million) Table 15. Global Targeted Drugs for Multiple Myeloma Revenue Market Share by Application (2022-2027) Table 16. Global Targeted Drugs for Multiple Myeloma Revenue (US$ Million) by Players (2016-2021) Table 17. Global Targeted Drugs for Multiple Myeloma Revenue Market Share by Players (2016-2021) Table 18. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Targeted Drugs for Multiple Myeloma as of 2020) Table 19. Date of Key Manufacturers Enter into Targeted Drugs for Multiple Myeloma Market Table 20. Global Targeted Drugs for Multiple Myeloma Top Players Headquarters and Area Served Table 21. Targeted Drugs for Multiple Myeloma Product Solution and Service Table 22. Global Targeted Drugs for Multiple Myeloma Players Market Concentration Ratio (CR5 and HHI) Table 23. Mergers & Acquisitions, Expansion Plans Table 24. Celgene Basic Information List Table 25. Celgene Description and Business Overview Table 26. Celgene Targeted Drugs for Multiple Myeloma Products, Services and Solutions Table 27. Revenue (US$ Million) in Targeted Drugs for Multiple Myeloma Business of Celgene (2016-2021) Table 28. Celgene Recent Developments Table 29. Exova Basic Information List Table 30. Exova Description and Business Overview Table 31. Exova Targeted Drugs for Multiple Myeloma Products, Services and Solutions Table 32. Revenue (US$ Million) in Targeted Drugs for Multiple Myeloma Business of Exova (2016-2021) Table 33. Exova Recent Developments Table 34. Natco Pharma Basic Information List Table 35. Natco Pharma Description and Business Overview Table 36. Natco Pharma Targeted Drugs for Multiple Myeloma Products, Services and Solutions Table 37. Revenue (US$ Million) in Targeted Drugs for Multiple Myeloma Business of Natco Pharma (2016-2021) Table 38. Natco Pharma Recent Developments Table 39. Intas Pharmaceuticals Basic Information List Table 40. Intas Pharmaceuticals Description and Business Overview Table 41. Intas Pharmaceuticals Targeted Drugs for Multiple Myeloma Products, Services and Solutions Table 42. Revenue (US$ Million) in Targeted Drugs for Multiple Myeloma Business of Intas Pharmaceuticals (2016-2021) Table 43. Intas Pharmaceuticals Recent Developments Table 44. Indiabulls Pharmaceutical Basic Information List Table 45. Indiabulls Pharmaceutical Description and Business Overview Table 46. Indiabulls Pharmaceutical Targeted Drugs for Multiple Myeloma Products, Services and Solutions Table 47. Revenue (US$ Million) in Targeted Drugs for Multiple Myeloma Business of Indiabulls Pharmaceutical (2016-2021) Table 48. Indiabulls Pharmaceutical Recent Developments Table 49. Cipla Basic Information List Table 50. Cipla Description and Business Overview Table 51. Cipla Targeted Drugs for Multiple Myeloma Products, Services and Solutions Table 52. Revenue (US$ Million) in Targeted Drugs for Multiple Myeloma Business of Cipla (2016-2021) Table 53. Cipla Recent Developments Table 54. Glenmark Pharmaceuticals Basic Information List Table 55. Glenmark Pharmaceuticals Description and Business Overview Table 56. Glenmark Pharmaceuticals Targeted Drugs for Multiple Myeloma Products, Services and Solutions Table 57. Revenue (US$ Million) in Targeted Drugs for Multiple Myeloma Business of Glenmark Pharmaceuticals (2016-2021) Table 58. Glenmark Pharmaceuticals Recent Developments Table 59. Dr Reddy's Laboratories Basic Information List Table 60. Dr Reddy's Laboratories Description and Business Overview Table 61. Dr Reddy's Laboratories Targeted Drugs for Multiple Myeloma Products, Services and Solutions Table 62. Revenue (US$ Million) in Targeted Drugs for Multiple Myeloma Business of Dr Reddy's Laboratories (2016-2021) Table 63. Dr Reddy's Laboratories Recent Developments Table 64. Qilu Pharmaceutical Basic Information List Table 65. Qilu Pharmaceutical Description and Business Overview Table 66. Qilu Pharmaceutical Targeted Drugs for Multiple Myeloma Products, Services and Solutions Table 67. Revenue (US$ Million) in Targeted Drugs for Multiple Myeloma Business of Qilu Pharmaceutical (2016-2021) Table 68. Qilu Pharmaceutical Recent Developments Table 69. Chia Tai-Tianqing Basic Information List Table 70. Chia Tai-Tianqing Description and Business Overview Table 71. Chia Tai-Tianqing Targeted Drugs for Multiple Myeloma Products, Services and Solutions Table 72. Revenue (US$ Million) in Targeted Drugs for Multiple Myeloma Business of Chia Tai-Tianqing (2016-2021) Table 73. Chia Tai-Tianqing Recent Developments Table 74. Hanson Pharm Basic Information List Table 75. Hanson Pharm Description and Business Overview Table 76. Hanson Pharm Targeted Drugs for Multiple Myeloma Products, Services and Solutions Table 77. Revenue (US$ Million) in Targeted Drugs for Multiple Myeloma Business of Hanson Pharm (2016-2021) Table 78. Hanson Pharm Recent Developments Table 79. Meidakang Huakang Pharmaceutical Basic Information List Table 80. Meidakang Huakang Pharmaceutical Description and Business Overview Table 81. Meidakang Huakang Pharmaceutical Targeted Drugs for Multiple Myeloma Products, Services and Solutions Table 82. Revenue (US$ Million) in Targeted Drugs for Multiple Myeloma Business of Meidakang Huakang Pharmaceutical (2016-2021) Table 83. Meidakang Huakang Pharmaceutical Recent Developments Table 84. Shandong Kongfu Pharmaceutical Basic Information List Table 85. Shandong Kongfu Pharmaceutical Description and Business Overview Table 86. Shandong Kongfu Pharmaceutical Targeted Drugs for Multiple Myeloma Products, Services and Solutions Table 87. Revenue (US$ Million) in Targeted Drugs for Multiple Myeloma Business of Shandong Kongfu Pharmaceutical (2016-2021) Table 88. Shandong Kongfu Pharmaceutical Recent Developments Table 89. J&J Basic Information List Table 90. J&J Description and Business Overview Table 91. J&J Targeted Drugs for Multiple Myeloma Products, Services and Solutions Table 92. Revenue (US$ Million) in Targeted Drugs for Multiple Myeloma Business of J&J (2016-2021) Table 93. J&J Recent Developments Table 94. Takeda Basic Information List Table 95. Takeda Description and Business Overview Table 96. Takeda Targeted Drugs for Multiple Myeloma Products, Services and Solutions Table 97. Revenue (US$ Million) in Targeted Drugs for Multiple Myeloma Business of Takeda (2016-2021) Table 98. Takeda Recent Developments Table 99. Amgen Basic Information List Table 100. Amgen Description and Business Overview Table 101. Amgen Targeted Drugs for Multiple Myeloma Products, Services and Solutions Table 102. Revenue (US$ Million) in Targeted Drugs for Multiple Myeloma Business of Amgen (2016-2021) Table 103. Amgen Recent Developments Table 104. Bristol Myers Squibb Basic Information List Table 105. Bristol Myers Squibb Description and Business Overview Table 106. Bristol Myers Squibb Targeted Drugs for Multiple Myeloma Products, Services and Solutions Table 107. Revenue (US$ Million) in Targeted Drugs for Multiple Myeloma Business of Bristol Myers Squibb (2016-2021) Table 108. Bristol Myers Squibb Recent Developments Table 109. Abbvie Basic Information List Table 110. Abbvie Description and Business Overview Table 111. Abbvie Targeted Drugs for Multiple Myeloma Products, Services and Solutions Table 112. Revenue (US$ Million) in Targeted Drugs for Multiple Myeloma Business of Abbvie (2016-2021) Table 113. Abbvie Recent Developments Table 114. Seattle Genetics Basic Information List Table 115. Seattle Genetics Description and Business Overview Table 116. Seattle Genetics Targeted Drugs for Multiple Myeloma Products, Services and Solutions Table 117. Revenue (US$ Million) in Targeted Drugs for Multiple Myeloma Business of Seattle Genetics (2016-2021) Table 118. Seattle Genetics Recent Developments Table 119. Karyopharm Therapeutics Basic Information List Table 120. Karyopharm Therapeutics Description and Business Overview Table 121. Karyopharm Therapeutics Targeted Drugs for Multiple Myeloma Products, Services and Solutions Table 122. Revenue (US$ Million) in Targeted Drugs for Multiple Myeloma Business of Karyopharm Therapeutics (2016-2021) Table 123. Karyopharm Therapeutics Recent Developments Table 124. PDL BioPharma Basic Information List Table 125. PDL BioPharma Description and Business Overview Table 126. PDL BioPharma Targeted Drugs for Multiple Myeloma Products, Services and Solutions Table 127. Revenue (US$ Million) in Targeted Drugs for Multiple Myeloma Business of PDL BioPharma (2016-2021) Table 128. PDL BioPharma Recent Developments Table 129. Roche Basic Information List Table 130. Roche Description and Business Overview Table 131. Roche Targeted Drugs for Multiple Myeloma Products, Services and Solutions Table 132. Revenue (US$ Million) in Targeted Drugs for Multiple Myeloma Business of Roche (2016-2021) Table 133. Roche Recent Developments Table 134. Sumitomo Basic Information List Table 135. Sumitomo Description and Business Overview Table 136. Sumitomo Targeted Drugs for Multiple Myeloma Products, Services and Solutions Table 137. Revenue (US$ Million) in Targeted Drugs for Multiple Myeloma Business of Sumitomo (2016-2021) Table 138. Sumitomo Recent Developments Table 139. Merck Basic Information List Table 140. Merck Description and Business Overview Table 141. Merck Targeted Drugs for Multiple Myeloma Products, Services and Solutions Table 142. Revenue (US$ Million) in Targeted Drugs for Multiple Myeloma Business of Merck (2016-2021) Table 143. Merck Recent Developments Table 144. Biogen Basic Information List Table 145. Biogen Description and Business Overview Table 146. Biogen Targeted Drugs for Multiple Myeloma Products, Services and Solutions Table 147. Revenue (US$ Million) in Targeted Drugs for Multiple Myeloma Business of Biogen (2016-2021) Table 148. Biogen Recent Developments Table 149. Schering-Plough Basic Information List Table 150. Schering-Plough Description and Business Overview Table 151. Schering-Plough Targeted Drugs for Multiple Myeloma Products, Services and Solutions Table 152. Revenue (US$ Million) in Targeted Drugs for Multiple Myeloma Business of Schering-Plough (2016-2021) Table 153. Schering-Plough Recent Developments Table 154. Glaxo Basic Information List Table 155. Glaxo Description and Business Overview Table 156. Glaxo Targeted Drugs for Multiple Myeloma Products, Services and Solutions Table 157. Revenue (US$ Million) in Targeted Drugs for Multiple Myeloma Business of Glaxo (2016-2021) Table 158. Glaxo Recent Developments Table 159. Chiron Basic Information List Table 160. Chiron Description and Business Overview Table 161. Chiron Targeted Drugs for Multiple Myeloma Products, Services and Solutions Table 162. Revenue (US$ Million) in Targeted Drugs for Multiple Myeloma Business of Chiron (2016-2021) Table 163. Chiron Recent Developments Table 164. North America Targeted Drugs for Multiple Myeloma Market Size by Country (2016-2021) & (US$ Million) Table 165. North America Targeted Drugs for Multiple Myeloma Market Size by Country (2022-2027) & (US$ Million) Table 166. Europe Targeted Drugs for Multiple Myeloma Market Size by Country (2016-2021) & (US$ Million) Table 167. Europe Targeted Drugs for Multiple Myeloma Market Size by Country (2022-2027) & (US$ Million) Table 168. Asia-Pacific Targeted Drugs for Multiple Myeloma Market Size by Region (2016-2021) & (US$ Million) Table 169. Asia-Pacific Targeted Drugs for Multiple Myeloma Market Size by Region (2022-2027) & (US$ Million) Table 170. Asia-Pacific Targeted Drugs for Multiple Myeloma Market Share by Region (2016-2021) Table 171. Asia-Pacific Targeted Drugs for Multiple Myeloma Market Share by Region (2022-2027) Table 172. Latin America Targeted Drugs for Multiple Myeloma Market Size by Country (2016-2021) & (US$ Million) Table 173. Latin America Targeted Drugs for Multiple Myeloma Market Size by Country (2022-2027) & (US$ Million) Table 174. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size by Players (2016-2021) & (US$ Million) Table 175. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size by Country (2022-2027) & (US$ Million) Table 176. Targeted Drugs for Multiple Myeloma Market Trends Table 177. Targeted Drugs for Multiple Myeloma Market Drivers Table 178. Targeted Drugs for Multiple Myeloma Market Challenges Table 179. Targeted Drugs for Multiple Myeloma Market Restraints Table 180. Research Programs/Design for This Report Table 181. Key Data Information from Secondary Sources Table 182. Key Data Information from Primary Sources List of Figures Figure 1. Global Targeted Drugs for Multiple Myeloma Market Size Year-over-Year 2016-2027 & (US$ Million) Figure 2. Global Targeted Drugs for Multiple Myeloma Market Size (US$ Million), 2016 VS 2021 VS 2027 Figure 3. Global Targeted Drugs for Multiple Myeloma Market Share by Regions: 2021 VS 2027 Figure 4. Global Targeted Drugs for Multiple Myeloma Forecasted Market Size Share by Region (2022-2027) Figure 5. North America Targeted Drugs for Multiple Myeloma Market Size (US$ Million) Growth Rate (2016-2027) Figure 6. Europe Targeted Drugs for Multiple Myeloma Market Size (US$ Million) and Growth Rate (2016-2027) Figure 7. Asia-Pacific Targeted Drugs for Multiple Myeloma Market Size (US$ Million) and Growth Rate (2016-2027) Figure 8. Latin America Targeted Drugs for Multiple Myeloma Market Size (US$ Million) and Growth Rate (2016-2027) Figure 9. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size (US$ Million) and Growth Rate (2016-2027) Figure 10. Global Targeted Drugs for Multiple Myeloma Market Size Share by Type in 2021 & 2027 Figure 11. Immunomodulator Market Size (US$ Million) YoY Growth (2016-2027) Figure 12. Proteasome Inhibitors Market Size (US$ Million) YoY Growth (2016-2027) Figure 13. Histone Deacetylase Inhibitors (HDACI) Market Size (US$ Million) YoY Growth (2016-2027) Figure 14. Monoclonal Antibody Market Size (US$ Million) YoY Growth (2016-2027) Figure 15. Other Market Size (US$ Million) YoY Growth (2016-2027) Figure 16. Global Targeted Drugs for Multiple Myeloma Market Size Share by Application in 2021 & 2027 Figure 17. Hospital Market Size (US$ Million) YoY Growth (2016-2027) Figure 18. Drug Center Market Size (US$ Million) YoY Growth (2016-2027) Figure 19. Clinic Market Size (US$ Million) YoY Growth (2016-2027) Figure 20. Other Market Size (US$ Million) YoY Growth (2016-2027) Figure 21. Targeted Drugs for Multiple Myeloma Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2020 Figure 22. Global Top 5 and Top 10 Players Targeted Drugs for Multiple Myeloma Market Share in 2020 Figure 23. North America Targeted Drugs for Multiple Myeloma Market Share by Country (2016-2027) Figure 24. United States Targeted Drugs for Multiple Myeloma Market Size (2016-2027) & (US$ Million) Figure 25. Canada Targeted Drugs for Multiple Myeloma Market Size (2016-2027) & (US$ Million) Figure 26. Germany Targeted Drugs for Multiple Myeloma Market Size (2016-2027) & (US$ Million) Figure 27. France Targeted Drugs for Multiple Myeloma Market Size (2016-2027) & (US$ Million) Figure 28. U.K. Targeted Drugs for Multiple Myeloma Market Size (2016-2027) & (US$ Million) Figure 29. Italy Targeted Drugs for Multiple Myeloma Market Size (2016-2027) & (US$ Million) Figure 30. Russia Targeted Drugs for Multiple Myeloma Market Size (2016-2027) & (US$ Million) Figure 31. Nordic Targeted Drugs for Multiple Myeloma Market Size (2016-2027) & (US$ Million) Figure 32. Rest of Europe Targeted Drugs for Multiple Myeloma Market Size (2016-2027) & (US$ Million) Figure 33. Asia-Pacific Targeted Drugs for Multiple Myeloma Market Share by Region (2016-2027) Figure 34. China Targeted Drugs for Multiple Myeloma Market Size (2016-2027) & (US$ Million) Figure 35. Japan Targeted Drugs for Multiple Myeloma Market Size (2016-2027) & (US$ Million) Figure 36. South Korea Targeted Drugs for Multiple Myeloma Market Size (2016-2027) & (US$ Million) Figure 37. Southeast Asia Targeted Drugs for Multiple Myeloma Market Size (2016-2027) & (US$ Million) Figure 38. India Targeted Drugs for Multiple Myeloma Market Size (2016-2027) & (US$ Million) Figure 39. Australia Targeted Drugs for Multiple Myeloma Market Size (2016-2027) & (US$ Million) Figure 40. Rest of Asia-Pacific Targeted Drugs for Multiple Myeloma Market Size (2016-2027) & (US$ Million) Figure 41. Latin America Targeted Drugs for Multiple Myeloma Market Share by Country (2016-2027) Figure 42. Mexico Targeted Drugs for Multiple Myeloma Market Size (2016-2027) & (US$ Million) Figure 43. Brazil Targeted Drugs for Multiple Myeloma Market Size (2016-2027) & (US$ Million) Figure 44. Rest of Latin America Targeted Drugs for Multiple Myeloma Market Size (2016-2027) & (US$ Million) Figure 45. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Share by Country (2016-2027) Figure 46. Turkey Targeted Drugs for Multiple Myeloma Market Size (2016-2027) & (US$ Million) Figure 47. Saudi Arabia Targeted Drugs for Multiple Myeloma Market Size (2016-2027) & (US$ Million) Figure 48. UAE Targeted Drugs for Multiple Myeloma Market Size (2016-2027) & (US$ Million) Figure 49. Rest of Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size (2016-2027) & (US$ Million) Figure 50. Bottom-up and Top-down Approaches for This Report Figure 51. Data Triangulation

Celgene Exova Natco Pharma Intas Pharmaceuticals Indiabulls Pharmaceutical Cipla Glenmark Pharmaceuticals Dr Reddy's Laboratories Qilu Pharmaceutical Chia Tai-Tianqing Hanson Pharm Meidakang Huakang Pharmaceutical Shandong Kongfu Pharmaceutical J&J Takeda Amgen Bristol Myers Squibb Abbvie Seattle Genetics Karyopharm Therapeutics PDL BioPharma Roche Sumitomo Merck Biogen Schering-Plough Glaxo Chiron